3646 results for «687»
3646 results
Structural and valvular innovations
19 May 2026 – From EuroPCR 2026
This session highlights the latest innovations in structural and valvular cardiology, featuring novel technologies such as a new self-expandable transcatheter aortic valve for aortic stenosis treatment and a temporary atrioventricular sequential pacing system. It also discusses non-clinical testing methodologies supporting U.S. market approvals, non-invasive ultrasound therapy...
Innovations in vascular therapies
19 May 2026 – From EuroPCR 2026
Discover cutting-edge innovations in vascular therapies highlighting novel technologies such as Pulse Intravascular Lithotripsy (IVL) for calcium modification and Amplitude Vascular Systems. The session also presents drug-free restenosis control strategies via CD31 camouflage coating promoting physiological-grade healing, emphasizing emerging solutions aimed at improving vascular intervention outcomes.
Large-bore venous access and vessel closure: all you need to know
19 May 2026 – From EuroPCR 2026
This session provides a comprehensive guide to large-bore venous access and vessel closure techniques, emphasizing best practices and the advantages of ultrasound-guided suture mediated vessel closure compared to traditional figure-of-eight suture methods. It also addresses strategies to avoid and manage potential complications encountered during these procedures.
Aortic paravalvular leak unmasked: different faces, different strategies
19 May 2026 – From EuroPCR 2026
Examine diverse clinical scenarios and management strategies for aortic paravalvular leaks (PVL), including complex percutaneous closures post-TAVI and surgical interventions. This session presents challenging cases demonstrating varied presentations and approaches such as mechanical valve loop utilization, highlighting the complexities and tailored solutions required for successful PVL...
Pivotal study on the ShortCut transcatheter aortic valve leaflet splitting device
16 May 2024
Coronary obstruction is a major concern in patients undergoing TAVI for degenerated bioprostheses (valve-in-valve [ViV]) and is associated with a 30-day mortality rate of around 50%.1 While several transcatheter techniques to lacerate bioprosthetic valve leaflets prior to TAVI placement (such as BASILICA) have been described, they are...
GLORIOUS - Efficacy of restrictive versus liberal oxygenation or Exenatide in patients undergoing coronary artery bypass grafting or aortic valve replacement – a randomised clinical trial
21 Nov 2024
Edoardo Zancanaro provides his take on the GLORIOUS trial presented by Sebastian Wiberg at AHA 2024 in Chicago.

Author